We investigated the structural elements in human von Willebrand factor (vWF) that influence binding affinity for platelet glycoprotein (GP) Ib using a dispase-digested vWF fragment as a prototype (residues Leu480/Va1481-Gly718 of the vWF subunit; Andrews et al. Biochemistry 28:8326, 1989). The major structural features of this fragment are a large Alloop formed by an intrachain disulfide bond between Cys509 and Cys695 and six 0-linked sugar chains. The fragment was chemically modified by (1) reduction and S-carboxyamidomethylation (R/A), (2) desialylation (DS), or (3) a combination of both (R/A-DS). The GPlb binding affinity of these fragments was basically evaluated by competitive binding HE INTERACTION OF von Willebrand factor (vWF) with platelet glycoprotein (GP) Ib is now accepted to be a key event in the initiation of platelet deposition at sites of vessel injury.' Earlier studies concerning identification of the binding sites responsible for this interaction using proteolytic fragments indicated that the GPIb binding domain of the vWF subunit resides on its amino acid residues 449-728, and that the vWF binding domain of GPIb resides on its N-terminal45-kD tryptic Since then, various approaches have been taken to identify more specifically these functional domains using synthetic peptides and/or recombinant fragment^.^.^ However, the most important question, namely, what mechanism modulates or regulates this interaction in vivo, remains to be answered. Because intact vWF in normal circulation never binds to GPIb, a certain rheologic force such as high shear stress or the interaction of vWF with subendothelial component(s) mimicking nonphysiologic modulators such as ristocetin or botrocetin is presumed to be responsible for the vWF binding to GPIb. ' To better understand the conformational and functional transition of vWF, the present study used a dispase-digested vWF fragment' as a prototype for the GPIb binding domain. Structurally, the fragment (residues 480/48 1-7 18 of the vWF subunit) appears to be a monomer containing a large loop formed by one intrachain disulfide bond (Cys509-Cys695) and six 0-linked sugar chains.'.'' Concerning functional features, this fragment retains the principal binding affinity for GPIb, heparin, and botrocetin.' We chemically modified this fragment by reduction followed by S-carboxyamidomethylation (FUA), by desialylation (DS), or by both (WA-DS) and then assessed its binding affinity toward GPIb using a wellcharacterized monoclonal antibody (MoAb) against GPIb (LJ-Ibl).h~ll
We investigated the structural elements in human von Willebrand factor (vWF) that influence binding affinity for platelet glycoprotein (GP) Ib using a dispase-digested vWF fragment as a prototype (residues Leu480/Va1481-Gly718 of the vWF subunit; Andrews with platelet glycoprotein (GP) Ib is now accepted to be a key event in the initiation of platelet deposition at sites of vessel injury.' Earlier studies concerning identification of the binding sites responsible for this interaction using proteolytic fragments indicated that the GPIb binding domain of the vWF subunit resides on its amino acid residues 449-728, and that the vWF binding domain of GPIb resides on its N-terminal45-kD tryptic Since then, various approaches have been taken to identify more specifically these functional domains using synthetic peptides and/or recombinant fragment^.^.^ However, the most important question, namely, what mechanism modulates or regulates this interaction in vivo, remains to be answered. Because intact vWF in normal circulation never binds to GPIb, a certain rheologic force such as high shear stress or the interaction of vWF with subendothelial component(s) mimicking nonphysiologic modulators such as ristocetin or botrocetin is presumed to be responsible for the vWF binding to GPIb. ' To better understand the conformational and functional transition of vWF, the present study used a dispase-digested vWF fragment' as a prototype for the GPIb binding domain. Structurally, the fragment (residues 480/48 1-7 18 of the vWF subunit) appears to be a monomer containing a large loop formed by one intrachain disulfide bond (Cys509-Cys695) and six 0-linked sugar chains.'.'' Concerning functional features, this fragment retains the principal binding affinity for GPIb, heparin, and botrocetin.' We chemically modified this fragment by reduction followed by S-carboxyamidomethylation (FUA), by desialylation (DS), or by both (WA-DS) and then assessed its binding affinity toward GPIb using a wellcharacterized monoclonal antibody (MoAb) against GPIb (LJ-Ibl).h~ll (residues Cys1786-and Arg1926-Sa2050 of vWF), and that of MoAb NMC-4 on residues Va1449-Lys728. NMC-4 inhibits vWFGPIb interaction in vitro" and also blocks complex formation between botrocetin and vWF." An anti-GPIb MoAb, LJ-Ibl (IgG), totally inhibits the vWF binding to GPIb mediated by ristocetin or botrocetin at the final concentration of approximately 50 pg/mL."
Purijicution of proteins. Methods for the purification of human vWF and two-chain botrocetin (hereafter called botrocetin) have been Bovine vWF was purified by the methods of Mascelli et al." A dispase-digested vWF fragment (residues Leu480/ Va1481-Gly728) was partially purified by heparin-sepharose affinity chromatography according to the method of Andrews et The fragment was then highly purified by reversed-phase high-performance liquid chromatography (RP-HPLC) on a SynChropak RP-8 column (10 X 250 mm) equilibrated with 0.1% trifluoroacetic acid with a gradient of acetonitrile from 0% to 60% and a flow rate of 2 mUmin (data not shown). The purified fragment (prototype, see Results) eluted at 45% acetonitrile was lyophilized and stored at -80°C. It was dissolved in 20 mmol/L HEPES-buffered saline, pH 7.4 (HBS), before use.
Gel electrophoresis. Sodium dodecyl sulfate (SDS)-15% polyacrylamide gel electrophoresis (PAGE) was performed as described previously." The gels were stained with Coomassie brilliant blue and/or periodic acid Schiff (PAS) reagent.'* Address reprint requests to Yoshihiro Fujimura, MD, Department of Blood Transfusion, Nara Medical College, Kashihara City, Nara, Japan.
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact. Desialylation. Desialylation (DS) of the prototype or WA fragment was performed by incubation with neuraminidase-linked agarose (5.0 U/mg protein) in 0. I molL sodium acetate buffer, pH 5.0, at 22°C for 2 hours. The desialylated fragments were separated from neuraminidase-linked agarose by centrifugation at 12,000g for 5 minutes, dialyzed against HBS, and then stored at -80°C until use.
Radioiodination of proteins. Proteins were radiolabeled by the method of Fraker and Speck'' using Iodogen with specific radioactivities ranging from 0.5 to 1.5 mCi/mg.
Competitive inhibition based on binding of biotinylated NMC-4
(I&) to vWF. Each well of a polystyrene microtiter plate was coated with 100 pL of a solution of MoAb 40-1 in 50 mmolL bicarbonate buffer, pH 9.6 (final concentration, 10 pg/mL), at 37°C for 2 hours. After removal of the solution, the wells were filled with 200 pL of 4% bovine serum albumin (BSA) in 50 mmol/L bicarbonate buffer, pH 9.6, at 37°C for 1 hour to block noncoated areas. They were washed three times with 250 pL of 40 mmol/L phosphatebuffered saline, pH 7.4, containing 0.05% Tween 20 (PBSIT-20) and then incubated with 50 HL of purified vWF ( 5 pg/mL) at 37°C for 2 hours. After incubation, the wells were washed three times with PBSIT-20.
In the assay, vWF fragments at various concentrations or HBS as a control, biotinylated MoAb NMC-4 (5 pg/mL), and BSA (5 mg/ mL) were incubated in a total of 125 pL incubation volume at room temperature for 1 hour. After incubation, two 50-pL aliquots of each mixture were placed into the microtiter plate wells with purified vWF captured through MoAb 40-1. After incubation at 37°C for 1 hour, the wells were washed three times with PBSIT-20 and then incubated with 50 pL of peroxidase-conjugated avidm solution (0.25 pg/mL) each at room temperature for 20 minutes. The wells were then washed three times with PBSIT-20, and 50 pL of 0.8 mg/mL o-phenylenediamine was added as the substrate to each well. The reaction was stopped after 10 minutes with 2 mol/L H2S04 and the absorbance was measured at 490 nm. Nonspecific binding was estimated in the presence of a 50-fold excess of unlabeled MoAb NMC-4. Binding of 100% indicates specific binding in the absence of any specific inhibitor.
Ristocetin-induced '2'I-labeled vWF binding to platelets. The assay method has been previously described in detail.' '251-labeled vWF, washed platelets, and ristocetin were used at final concentrations of 5 pg/mL, 1 X 10*/mL, and 1 mg/mL, respectively. Binding of 100% indicates specific binding in the absence of any specific inhibitor.
Competitive inhibition based on the binding of '2'l-labeled W-161 (IgC) to GPZb. Inhibition assay was performed according to the method of Sugimoto et al. ' ." vWF fragments at various concentrations, '251-labeled MoAb U-Ibl (IgG, 10 pg/mL), and washed platelets ( I X 1 0'hL) were incubated at room temperature for 30 minutes in the absence or presence of ristocetin (1 mg/mL) or botrocetin (5 pg/mL). After incubation, platelets were centrifuged through 20% sucrose to separate free ligand, and the platelet-bound radioactivity was determined with a gamma-scintillation counter. Nonspecific binding was estimated in a mixture containing the same reagents and a 50-fold excess of unlabeled MoAb LJ-Ibl. Binding of 100% indicates specific binding in the absence of any specific inhibitor.
Direct binding of '2'I-labeled bovine vWF to platelets. '''I-labeled bovine vWF ( 5 pg/mL) and human washed platelets (1 X 10' 1 mL) were incubated with or without competitive inhibitors at room temperature for 30 minutes in the absence of ristocetin or botrocetin. Platelet-bound radioactivity and nonspecific binding were determined essentially as described above. Binding of 100% indicates specific binding in the absence of any specific inhibitor.
Shear-induced platelet aggregation (SIPA). The procedures used to measure SIPA have been previously described in detail.' Trisodium citrate as an anticoagulant was used at a final concentration of 0.01 l mol/L. Platelet-rich plasma (PRP) from a normal individual was prepared as described? In each experiment, vWF fragment at various concentrations, anti-vWF MoAb NMC-4 ( I O pg/ mL), an anti-GPIb MoAb LJ-Ibl (50 pg/mL), or HBS as a control was added to PRP. The platelet count of the mixtures was then adjusted to 300 X 103/pL using homologous instead of analogous platelet-poor plasma (PPP). A shear stress gradient (6 to 108 dyne/ cm2) was applied to the PRP mixture. After exposure to 6 dyne/cm' for an initial 15 seconds, shear stress was increased to 12 dyne/cm' over the next 90-second period (low shear stress). Stress was then increased linearly from 12 to 108 dyne/cm2 over the following 120 seconds, and finally kept constant at 108 dyne/cm2 for the last 125 seconds (high shear stress).
RESULTS
Characterization of the dispase-digested v WF ,fragment (prototype) and its chemically modiJed forms.
On SDS-15% PAGE analysis under nonreducing conditions, the prototype fragment purified by RP-HPLC exhibited an electrophoretic mobility faster than its WA counterpart (Fig l ) . However, their mobilities were almost identical and showed a molecular mass of 39/34 kD under reducing conditions. The prototype fragment was fully biologically active in terms of its inhibitory action on ristocetin-or botrocetin-induced vWF binding to GPIb and the binding of botrocetin to vWF,' indicating that one disulfide bond formed between Cys509 and Cys695 within the molecule, and its biologic function remained unchanged even after purification by RP-HPLC at pH 3.2 and with 45% acetonitrile (data not shown). After DS, both the prototype and the WA fragments showed electrophoretic mobilities faster than their counterparts with the sugar chains intact on SDS-PAGE analysis. The total loss of PAS staining activity after neuraminidase treatment of the fragments was confirmed on the relevant SDS-PAGE gels (data not shown). These four fragments are used through out this report with the following abbreviations: (1) prototype, ( 2 ) WA, (3) DS, and (4) WA-DS fragments.
Immunoreactivity of the jbur fragments with anti-vWF
MoAb NMC-4. NMC-4 is one of the best inhibitors of vWF-GPIb binding in vitro.
Although the epitope of this antibody resides on residues 449-728 of the vWF subunit, its immunoreactivity with vWF is dependent on a conformation formed by a disulfide-bridged (Cys.509 and Cys695) loop."
On Western blotting analysis, none of the four fragments reacted with NMC-4 (data not shown), although the tryptic 97-to 116-kD fragment is highly immunoreactive."
However, in a liquid-phase competitive binding assay, the prototype fragment clearly inhibited the interaction of NMC-4 with vWF in a dose-dependent manner (Fig 2) . However, the WA-DS fragment exhibited much lower apparent immunoreactivity toward NMC-4. Moreover, the DS and WA fragments showed lower immunoreactivity toward NMC-4 than their respective counterparts, suggesting that both native terminal sialic acids in the sugar chains and the disulfidebridged (Cys.509-Cys695) loop are important for maintaining the three-dimensional structure required for the optimal immunoreactivity of NMC-4. inhibition assay based on the binding of "'1-labeled LJ-lbl (IgG) to GPIb, relative binding affinity of the four fragments to GPlb was measured as described in Materials and Methods.
In the absence of exogenous vWF modulator, both the W A and the WA-DS fragments (with or without desialylation) exhibited dose-dependent inhibition at closely similar IC50 ranges (1.1 to 1.2 pmol/L). In contrast, the nonreduced fragments (prototype and DS) had only minimal effects (Fig 3) . However. in the presence of ristocetin ( 1 mglmL). both the prototype and WA fragments showed lower 1C5Os (approximately 0.2 pmol/L), whereas the desialylated fragments (DS and WA-DS) showed much higher values ( I to IO pmol/L). Moreover, in the presence of botrocetin (S pg/mL), another vWF modulator, all four fragments showed closely similar ICSOs (around 0.05 pmol/L).
Effect of the .four ,fragments on ristocerin-induced Iz5I-vWF binding to GPlb. The results obtained above strongly suggested that ristocetin cannot properly modulate the function of the desialylated vWF fragments (Fig 4) .
In the presence of regular concentration of ristocetin ( I mg/mL), the 1CSOs of both the WA and prototype fragments ranged from 0.2 to 0.3 pmol/L. However, the two desialylated fragments (DS and WA-DS), did not show 50% inhibition of '''I-vWF binding to GPlb even at I O pmol/L.
Effect qf the .four fragments on direct '251-bovine vWF binding to GPlb. Both the WA and the WA-DS fragments exhibited a dose-dependent inhibition on '"I-bovine vWF binding to GPlb with almost the same ICS0s (0.4 and 0.5 pmoVL). However, the nonreduced fragments did not show any significant inhibition on that binding (Fig 5 ) .
Effects of the prototype and WA.fragment.7 on S P A . The functional importance of the disulfide-bridged (CysS09-Cys695) loop structure of vWF was also evaluated by its inhibition of SIPA. Neither the prototype (Fig 6A) nor the WA fragment (Fig 6B) a low shear rate at a final concentration of 10 pmol/L. Under a high shear rate, only the R/A fragment inhibited aggregation in a dose-dependent manner, and total inhibition was observed at the final concentration of 5 pmol/L (Fig 6B) . The prototype fragment, however, had almost no effect on aggregation under a high shear rate at any concentration up to 10 ,umol/L (Fig 6A) . In a control experiment, Fig 6A also shows the complete inhibition by MoAb NMC-4 (against vWF) or LJ-Ibl (against GP Ib) of aggregation under a high shear rate.
DISCUSSION
In 198 1, De Marco and Shapiro2" demonstrated that desialylated vWF spontaneously binds to platelets and initiates their aggregation. Since then, many studies on the vWFGPIb interaction have focused on the carbohydrate moieties and multimeric structures of vWF.' Our study' and others2','* have shown that a restricted region of the vWF subunit is responsible for this binding. Noteably, the reduced and alkylated 52/48-kD fragment (residues 449-728 of the vWF sub- within the GPIb binding domain. This suggests that these mutant molecules may have some conformational difference from normal vWF. Furthermore, independent testing by two different groups of a panel of overlapping synthetic peptides encompassing residues 449-728 of vWF showed the GPIb binding domain to be located on two discrete regions. One group located the domain on two discontinuous regions (residues 474-488 and 694-70g4) and the second on residues 5 14-542. ' Gralnick et alz6 have demonstrated that a recombinant vWF fragment (residues 504-728) with a single intrachain disulfide bond (Cys509-Cys695), expressed in E coli, inhibits vWF-GPIb interactions and platelet adhesion at high shear stress. Subsequently, Sugimoto et al" have reported that a similar recombinant vWF fragment (residues 508-696) with an intrachain disulfide bond (Cys509-Cys695) is fully active in regard to binding ability to GPIb, but any segmental lack within this loop region diminished the original activity.
In the present study, we used a monomeric dispase vWF fragment.x Because this monomeric fragment has been shown to be the minimal functional unit of the GPIb binding that can be obtained by proteolytic cleavage of vWF, we presumed that it could be used as a probe to evaluate the influence of the intrachain disulfide bond (Cys509-Cys695) and six 0-linked sugar chains in this region on the vWF-
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GPIb interaction. The different structural features of the four fragments were first characterized in three ways, ie, by (1) SDS-PAGE analysis, (2) PAS staining, and (3) immunoreactivity with anti-vWF MoAb NMC-4. Their relative binding affinity to GPIb was then evaluated by the LJ-Ibl (a receptor blocker for vWF) binding assay to GPIb.'.' ' The results clearly demonstrated that, in the absence of any vWF modulator, the WA fragments, regardless of their desialylated status, showed much higher affinity for GPIb than their counterparts with the disulfide bond intact. Specifically, the presence of a disulfide-bridged loop structure in this domain downregulates the vWF binding affinity to GPIb. Direct binding studies using l2'1-bovine vWF also supported this concept. The dose-dependent inhibition of platelet aggregation under a high shear stress by the R/A fragment visualized this scenario, and conducted a final conclusion on this issue.
In the presence of 1 mg/mL ristocetin, the prototype and WA fragments showed closely similar binding affinity toward GPIb, in contrast to the respective desialylated fragments, which showed much lower affinity for GPIb. These results were derived from two different competitive assays based on LJ-Ibl and conventional vWF binding to GPIb. Interestingly, in the presence of botrocetin, these four fragments almost equally inhibited LJ-Ibl binding to GPIb with much lower ICSOs (by two orders magnitude) than in the absence of botrocetin. Because botrocetin is known to bind to vWF, producing an activated complex with binding ability to GPIb, the results indicate that neither the disulfide-bridged structure nor the terminal sialic acids are critical for botrocetin's modulation of vWF function.
In summary, this study shows that the intrachain disulfide bond formed by Cys509-Cys695 plays a key role in preventing the random binding of native vWF to platelet GPlb in normal circulation. Experiments using the nonphysiologic vWF modulators ristocetin and botrocetin suggest that the activated complexes formed between the four different fragments and botrocetin may have a similar conformation for GPIb binding, whereas the interaction of the four fragments with ristocetin is more complex because of the strong influence of the terminal sialic acids present in the fragments.
